Skip to main content

Who we are

ReproNovo was founded in 2021 by a team with proven expertise in the reproductive medicine and women’s health space. With years of immersion in this field, we possess deep knowledge of drug development, regulatory affairs and business development in these therapeutic areas, the treatment landscape and patient needs.

Our team has successfully brought numerous therapies to market. Drawing upon our in-depth experience in designing and executing clinical programs, we are strongly committed to delivering innovative therapeutics solutions for male and female infertility and pioneering treatment options for conditions like adenomyosis.

In pursuit of this objective, we have built a company aimed at addressing critical gaps in the landscape of reproductive medicine and women’s health worldwide.

ReproNovo is headquartered in Lausanne, Switzerland, with its primary development team located in Copenhagen, Denmark and an additional development site in Barcelona, Spain.

Meet our team

We are united by our strong passion for developing effective solutions for patients who dream about having a baby. Our unique team with diverse backgrounds in science, development, regulatory affairs, deal-making and more is dedicated to advancing reproductive medicine and women’s health.

Board of Directors

Trusted experts guiding our mission.

Investors that back our vision

We are backed by renowned international investors who share a deep knowledge of reproductive medicine and women’s health—and who share our commitment to delivering meaningful innovation to patients in need.

”

  • As approximately one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies and the commercialization of treatments with transformative benefits for patients. We were highly impressed by the ReproNovo team, whose members have a strong track record in this field, having brought a number of compounds successfully through clinical development and onto the market. Their deep understanding of the field will enable them to effectively address critical unmet needs that have a strong impact on society.

    – Ksenija Pavletic, Partner & Chief Commercial Officer, Jeito Capital –

  • We are proud to support a company working to address critical gaps in reproductive medicine and women’s health. This includes indications such as adenomyosis where no treatments currently exist and other areas, including male infertility where limited options are available and female infertility where the aim is to improves success rates. We look forward to being a part of ReproNovo’s journey for the long term as they strive to improve the global treatment landscape and bring novel solutions to patients urgently in need of effective therapies.

    Dr. Zina Affas Besse, Partner & Deputy Head of Healthcare Private Equity, AXA IM Alts

  • ReproNovo’s innovative approach to male and female infertility can significantly benefit the fertility journey for an increasingly large population worldwide. As the founding investor, we are proud to continue supporting the company to deliver their vision, to redefine the future of fertility treatments, and welcome this highly dedicated investor group, who shares that vision.

    Hakan Goker, Managing Director, M Ventures

  • ReproNovo is pioneering solutions for some of the most overlooked challenges in reproductive medicine and women’s health. We have confidence in their science and are proud to support their commitment to innovation and their mission of bringing novel options to patients. We look forward to seeing their breakthroughs transform women’s health and infertility worldwide.

    Guillem Laporta, Partner, Ysios Capital

  • ReproNovo’s bold vision and commitment to developing treatments for infertility and other areas of women’s health set them apart in reproductive medicine. With less-than-ideal and in some cases non-existent treatments for these indications, ReproNovo’s innovative pipeline and strong experience offer the potential to transform care for countless patients. We are proud to support the company and believe in their ability to drive meaningful change in this field.

    Katie Sunnucks, Investment Director, ALSA Ventures

    Would you like to keep up to date with the latest from ReproNovo?
    Click here to subscribe for our regular news

    Subscribe Now